RAPT Therapeutics Shares Plunge Premarket on FDA Study Hold

Shares of RAPT Therapeutics plummeted more than 65% in premarket trading Tuesday after a serious adverse event prompted the U.S. Food and Drug Administration to place a clinical hold on a pair of the biopharmaceutical company's studies in inflammatory diseases.